INTRODUCTION
The so-called tandem autologous (auto)-allogeneic (allo) stem cell transplantation (SCT) is a sequential two-step procedure which combines tumor burden reduction by high-dose chemotherapy followed by auto-SCT and the graft-versus-myeloma effect (GVM) mediated by immunocompetent lymphocytes following allo-SCT (1) (2) . The feasibility of the tandem auto-allo-SCT, initially described in resistant lymphomas (3) has been demonstrated by several studies in multiple myeloma (MM) (4) (5) (6) (7). However, due to a relatively limited number of patients, different issues related to tandem SCT remain unsolved. In the largest series reported so far (8) (9) including 102 MM patients, median overall survival (OS) was more than 6 years and median event-free survival (EFS) was 3 years.
Another retrospective study on 17 MM patients receiving tandem auto-allo-SCT reported 2 year-OS and EFS of 74% and 56%, respectively (10) . Bruno published a series on 100 newly diagnosed MM receiving tandem auto-allo-SCT (11) . With a median follow-up >5 years, median EFS was 37 months.
Altogether these results indicate that tandem auto-allo-SCT is a potential treatment for MM patients with beneficial impact on survival.
To further characterize the benefit of tandem auto-allo-SCT in MM, studies comparing its efficacy to double auto-SCT have been conducted in newly diagnosed MM patients. In the French study of the IFM, high-risk patients (with β2 microglobulin >3.5 mg/L and chromosome 13 deletion (del13)) were randomized either to receive a double auto-SCT or a tandem auto-allo-SCT (12) (13) .
The comparison of the two treatment arms suggested a trend for a better OS in the double auto-SCT arm (p=0.07). EFS was not statistically different in the two arms (p=0.58). In the Italian study, OS and EFS were significantly better in the tandem auto-allo-SCT arm (p=0.01 and 0.02) (14) . The Spanish study of the PETHEMA randomized MM patients not in complete response (CR) or near CR after a first auto-SCT either to receive a second auto-SCT or a nonmyeloablative allo-SCT (15) . This study did not find any significant difference in OS and EFS between the two arms. The conflicting conclusions of these three studies might be attributed to differences in the patients' prognostic factors (high versus standard risk), the randomization criteria for tandem (HLA-matched donor available versus quality of response post-auto-SCT) and the allogeneic conditioning regimen (TBI 2 Gy versus Fludarabine-Melphalan).
To potentially identify the best candidates to tandem auto-allo-SCT, recent prospective studies included cytogenetic data. MM patients were randomized between double auto-SCT and tandem autoallo-SCT when an HLA-matched sibling donor was available. In the US BMT CTN102 phase III trial, there was no significant benefit in survival between the two treatment arms, both in high risk (β2 microglobulin ≥4 mg/L and del13) and in standard risk patients, where 3 year-OS in the tandem autoallo-SCT arm was 59% and 77%, respectively (16) (17) . In the recently published EBMT study, 5 year-OS was 65% and 58% in the tandem auto-allo-SCT and auto-SCT arms, respectively (p=0.006) (18).
For patients with del13, OS was 69% in the auto-allo-SCT versus 55% in the auto-SCT arm, with p=0.003. For patients with no del13, OS was not statistically different between the two arms. Thus, an improvement or trend for an improvement was observed in both standard (no del13) and high risk 5 (presence of del13) prognostic groups receiving tandem auto-allo-SCT compared to auto-SCT arm. In the German DSMMM group, for newly diagnosed MM patients with del13, 3 year-OS was 60% in the tandem auto-allo-SCT arm, not significantly different from the double auto-SCT arm (19). In upfront setting, the benefit in survival of tandem auto-allo-SCT and the best candidates to this procedure remain unclear.
In this context, we report the French experience of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) on tandem auto-allo-SCT in MM. On the largest series published thus far, we present long-term follow-up data and a prognostic factor analysis.
DESIGN AND METHODS

Patients
This was a retrospective registry-based study which included 146 patients who had undergone tandem auto-allo-SCT at 20 SFGM-TC centers for MM. The patients included in the study had fully completed the two-step modality of a planned tandem auto-allo transplantation. No treatment had to be administered between auto and allo-SCT of the tandem. The decision to perform tandem was taken by each participating center. Due to the retrospective nature of the study, the decision's criteria to perform tandem or not, could not be further characterized and the number of withdrawn patients at any of the step before auto-SCT or between auto-SCT and allo-SCT of the tandem could not be assessed. For each patient, the following data were recorded at diagnosis in the French SFGM-TC database: demographics (age, gender), biologics (level and type of serum paraprotein and urinary light chains, serum level of creatinine and β2 microglobulin, and cytogenetics whenever available). 
Tandem auto-allo procedure
Patients included in this study received induction regimen before tandem auto-allo-SCT according to institutional protocols or according to the Intergroupe Francophone du Myélome (IFM) guidelines. A treatment line before tandem auto-allo-SCT was defined as an induction regimen which did not include an autologous transplantation. Autologous stem cell mobilization was performed using G-SCF with or without intermediate-dose (3 g/m²) cyclophosphamide (Cy) depending on the policy of the participating center. After peripheral blood stem cells (PBSC) collection, patients underwent auto-SCT prepared by high-dose chemotherapy (Melphalan 200 or 140 mg/m² according to renal function). A tandem autoallo-SCT performed after a single line of treatment, ie with no preceding auto-SCT, was defined as upfront tandem. Chemosensitive disease was represented by complete response (CR), very good 6 partial response (VGPR), partial response (PR) and minimal response (MR), whereas refractory disease was represented by stable disease (SD) and progressive disease (PD). For autologous and allogeneic transplantations, supportive care was performed according to each centers' policy.
Assessment of response
Based on clinical and laboratory data recorded in the SFGM-TC database and collected from participating centers for the purpose of this analysis, disease response was evaluated according to IMWG criteria (21) before auto-SCT, between auto and allo-SCT of the tandem, and within 6 months following completion of the planned procedure of tandem (best response after allo-SCT).
Study end points
The primary end points were the overall response rate (ORR), EFS, OS and transplant-related mortality (TRM) following completion of the complete tandem procedure. We also assessed engraftment, chimerism, acute and chronic GVHD (aGVHD and cGVHD). PBSC or bone marrow (BM) donor-recipient chimerism was performed after allo-SCT at usual given days and as clinically indicated, through analysis of DNA microsatellite polymorphisms by polymerase chain reaction (PCR) in sex matched cases and through conventional cytogenetic analysis by G-banding or FISH studies for the Y-chromosome in sex-mismatched cases. Diagnosis and clinical grading of GVHD were performed according to established criteria (22) (23). Patients who had a successful engraftment and survived for at least 4 weeks were evaluable for aGVHD, whereas patients surviving for at least 100 days were evaluable for cGHVD. TRM was defined as deaths related to allo-SCT of the tandem.
Statistical analysis
Overall survival was calculated from the time of inclusion in the study (ie from the date of allo-SCT of the tandem) until the date of death from any cause. Data on patients who did not die were censored on the last date they were known to be alive. Event-free survival was calculated from the date of allogeneic transplantation until the date of disease progression, disease relapse, or patient death or the date of the last visit. The probabilities of OS, EFS were estimated using the Kaplan-Meier method.
The occurrence of TRM and GVHD was estimated by the cumulative incidence method. The impact of several variables on OS, EFS and TRM was tested using Log rank tests. The factors found to be statistically significant (p≤0.05) in univariate analyses were entered into a stepwise Cox model to determine their independent contribution to survival (OS, EFS, TRM) (24).
RESULTS
Patient characteristics at diagnosis (Table 1)
Forty patients (56%) displayed del13. For 34 patients, this aberration was isolated, 5 patients had del13 accompanied with t(4;14) and 1 patient had both del13 and del17. 
Characteristics of the tandem auto-allo-SCT (
Morbidity and causes of death after tandem auto-allo-SCT procedure (Table 4)
Acute GVHD developed in 55 patients (38%). 37 patients (26%) had grade I-II aGVHD. Acute grade III-IV GVHD occurred in 18 patients (12%) and was fatal in 6 patients. Chronic GVHD was evaluable in 141 patients. 43 patients (30%) developed cGVHD. 17 patients had limited (12%) and 26 (18%) extensive stage, respectively. Extensive cGVHD was lethal in one patient. Infection developed in 53 patients (36%). TRM at day 100, and 1 year after allo-SCT was 6.3% (95% CI 3.4-11.5) and 15% (95% CI 10-22), respectively. Among tandem-related complications, 21 patients died of infection, including 7 bacterial, 4 viral, 4 fungal infections. Seven patients died of GVHD (6 aGVHD and 1 cGVHD) and 1 patient died of veno-occlusive disease. Five patients died from a second hematological disease or cancer, including 1 acute myeloid leukemia, 1 B-cell lymphoma and 1 pancreatic cancer.
For two patients, the type of second cancer was not specified. Median follow-up after the tandem procedure was 47.5 months (range 1.2-132 months). In univariate analysis, younger donor's age was significantly associated with a reduced TRM, with a median TRM of 8% (95% CI 3-16) when ≤50 years versus 24% (95% CI 15-36) when >50 years, with p=0.006. Supplemental Table A summarizes the results of univariate analysis for TRM. Two independent factors were found to be predictive of TRM post tandem auto-allo-SCT in the Multivariable Cox's regression models. Donor's age >50 years was associated to a worse TRM with hazard ratio (HR)=3.86 (95% CI 1.49-9.97), p=0.006. The number of auto-SCT before the tandem was also an independent factor of worse TRM with HR=1.91 (95% CI 1.15-3.19), p=0.01. Supplemental Table B summarizes the results of multivariable analysis for TRM.
Survival
EFS post-tandem reached 27% (95% CI 19-36). EFS curve demonstrates a continuous risk of disease recurrence with no plateau. OS post-tandem was 48% (95% CI 39-57) (Figure 1 ). Younger patient age at diagnosis (≤50 years) was associated to an improved survival with p=0.05 for OS and p=0.02 for EFS. Median OS of patients for which auto-allo SCT was performed as upfront procedure, was significantly improved with 56% (95% CI 45-67) versus 34% (95% CI 21-50), with p=0.02 ( Figure 2A) .
As for OS, median EFS of patients transplanted upfront was significantly higher with 36% (95% CI 26-47) versus 11% (95% CI 4-26), with p=0.005 ( Figure 2D ). Univariate analysis for OS and EFS did not show any significant difference according to cytogenetics (presence or absence of del13) ( Figure   2BE ). OS for patients without del13 was 60% (95% CI 40-78) versus 43% (95% CI 28-59) for those with del13, with p=0.2. EFS for patients without del13 reached 26% (95% CI 13-46) versus 18% (95% CI 8-34) for those with del13, with p=0.53. No statistically significant difference in survival was observed, according to the type of donor (related or unrelated), with 51% (95% CI 41-60) versus 31% (95% CI 14-56) for OS and 26% (95% CI 18-36) versus 27% (95% CI 12-50) for EFS. As for the type of donor, no statistically significant difference in OS and EFS was observed with the type of allogeneic conditioning regimen (myeloablative or nonmyeloablative) (Supplemental Table A ). Younger donor's age was significantly associated with a better OS, with a median OS of 54% (95% CI 41-67) when ≤50 years versus 41% (95% CI 29-55) when >50 years, with p=0.02 ( Figure 2C) . As for OS, younger donor's age was also associated with an improved EFS, with a median EFS of 35% (95% CI 24-48) when ≤50 years versus 16% (95% CI 8-28) when >50 years, with p=0.005 ( Figure 2F ). Supplemental Table A summarizes the results of univariate analysis for OS and EFS. Two independent factors were found to be predictive for both overall survival and event-free survival post tandem auto-allo-SCT in the Multivariable Cox's regression models. Donor's age >50 years was associated to a worse OS with hazard ratio (HR)=1.99 (95% CI 1.22-3.25), p=0.006. Higher donor's age was also associated to a worse EFS with HR=2.13 (1.40-3.25), p=0.0004. Achievement of full chimerism post tandem was associated to a better outcome with HR=0.46 (95% CI 0.25-0.86), p=0.02 for OS and HR=0.35 (95% CI 0.2-0.61), p=0.0002 for EFS, respectively. Supplemental Table B summarizes the results of multivariable analysis for OS and EFS.
DISCUSSION
We identified upfront tandem as a significant factor for improved survival after tandem transplantation. When tandem auto-allo-SCT was performed as an upfront procedure, EFS was 36% (95% CI 26-49) versus 11% (95% CI 4-26), with p=0.005. In our multivariable analysis, upfront tandem was an independent factor of better EFS with HR=0.56 (95% CI 0.37-0.85), p=0.006. In a prospective setting, on 100 newly diagnosed MM patients receiving tandem auto-allo-SCT, Bruno reported a 5 year-OS of 65% and 5 year-EFS of 40% respectively, with a median follow-up of 5 years (11) . In a small retrospective series of 23 relapsed MM patients, Karlin has shown the feasibility of tandem transplantation with 2 year-OS of 61% (25). However, median follow-up was short (27.4 months) and the recently published EBMT study has emphasized the need of a prolonged follow-up to see the benefit on survival of tandem auto-allo-SCT emerging (18). Finally, in the Seattle series of 102 MM patients, 5 year-OS was 64% and 5 year-PFS 36% respectively, with a median follow-up of 6.3 years (8) . In this series, only 20% of the patients had received >1 induction treatment for relapsed/refractory MM with no autologous transplantation prior to tandem auto-allo-SCT. In the multivariable analysis, time >10 months between treatment start and auto-SCT of the tandem was correlated with shorter survival, but number of treatment lines before tandem failed to reach significance. In our series, 47% of the patients had received >1 line of treatment before tandem. Our results suggest that considering tandem auto-allo-SCT early in the course of MM should further improve the benefit of tandem transplantation in the long-term control of the disease.
Incidence of acute and chronic GVHD was low in our cohort. In the Seattle series (8), among 102 patients transplanted after TBI 2 Gy +/-Fludarabine; 42% experienced grade II-IV aGVHD and 74% extensive cGVHD. In the PETHEMA study (15) , for the 25 patients receiving allo-SCT from HLA sibling donors after Fludarabine and Melphalan, the incidence of grade II-IV aGVHD was 32%, and incidence of cGVHD 66%. Low incidence of GVHD in our study was possibly correlated to the important number of patients (91, 62%) experiencing a T-cell depletion procedure, either ex vivo (7 patients) or in vivo with ATG (84 patients, 58%). The incidence of GVHD we report here is similar to that of the studies including ATG as part of the conditioning regimen (26). In the study published by Kröger (10), patients received a regimen based on Fludarabine, Melphalan and ATG (rabbit, Fresenius) (30 mg/kg). Incidence of grade II-III aGVHD was 38% and cGVHD 40% respectively. In the French IFM study (12) (13), 46 MM patients of the auto-allo-SCT arm received Busulfan, Fludarabine and ATG. Patients received ATG (rabbit, Genzyme) at 2.5 mg/kg during 5 days. Incidence of grade II-IV aGVHD was 23.9% and extensive cGVHD 35.7%. Compared to IFM study, we used a reduced dose of ATG at 2.5 mg/kg during 2 to 3 days. However, we did not observe a higher rate of GVHD.
Beside its low incidence, GVHD was rarely fatal in our study with 7 deaths related to GVHD (6 aGVHD and 1 cGVHD).
We report a TRM at 1 year of 15%. In the relapse setting, Karlin reported on a single centre experience on tandem auto-allo-SCT in 23 MM patients (25). TRM at 1 year was 17%. Our cohort included heavily treated patients with 53 (36%) having a prior auto-SCT before the tandem and 69 (47%) treated by more than one line of treatments before tandem auto-allo-SCT. In the series of Seattle (8) (9), with a median follow-up of 6.3 years, TRM was 18% but none of the patients had received an auto-SCT prior to the tandem auto-allo-SCT. As for patients' characteristics, transplant characteristics in our study included higher-risk transplantation, with 17 patients (12%) receiving a myeloablative allogeneic conditioning and 31 patients (21%) transplanted with unrelated donors. In the studies mentioned above, MM patients received a nonmyeloablative conditioning regimen based on TBI 2 Gy. Furthermore, all patients except 10 among 23 in the study by Karlin (25), were transplanted with HLA-identical sibling donors. In our univariate analysis, the number of prior auto-SCT before tandem auto-allo-SCT was a significant factor for TRM, with p=0.03. There was a trend for a lower TRM when tandem was performed as an upfront procedure, with a TRM of 10% (95% CI 5-20) versus 20% (95% CI 12-31), with p=0.08. The TRM of patients with no prior auto-SCT or one prior auto-SCT was not different (12 and 14% respectively) as opposed to a much higher TRM (33%) for patients with 2 auto-SCT prior to the tandem. These results could explain the lack of significance of upfront tandem for TRM. Altogether, our results confirm the feasibility of tandem auto-allo-SCT in this highly pretreated cohort.
In our cohort, 48 patients (70%) had a high β2 microglobulin (>3 mg/L). This parameter was not significantly associated to a poorer survival, with p=0.54 for OS and p=0.98 for EFS respectively.
In the Seattle series (8) (9), only 44% of the patients had a high β2 microglobulin (>3.5 mg/L). In multivariable analysis, authors identified β2 microglobulin >3.5 mg/L at diagnosis as a predictive factor of worse outcome with p=0.03 and 0.04 for OS and PFS respectively. No consistent conclusion could be drawn on the prognostic impact of del13, based on the poor exhaustivity of FISH data (18 patients).
In our study, presence of del13 was not predictive of a worse outcome with an OS of 43% (95% CI 28-59) when del13 was present versus 60% (95% CI 40-78), with p=0.2. Recently, Gahrton reported an improvement in survival for patients with del13 receiving tandem auto-allo-SCT compared to auto-SCT arm (18). Our results are in accordance with those previously published by IFM (12) (13). In the IFM 99.03 study, no benefit in survival was demonstrated in the tandem auto-allo-SCT arm and authors concluded that tandem might be best indicated for standard risk patients. Furthermore, all patients in the two above studies and 90% in the Seattle series had received an anthracyclin-based induction (VAD) or similar treatment. Based on the results of IFM 2005 study showing the superiority of Bortezomib-Dexamethasone (VD) in response regardless of adverse cytogenetics, VAD has been progressively replaced by VD (27) (28). Therefore, 14 patients (10%) of our cohort received VD as induction, which could have contributed to the lack of significance of del13 on survival after tandem auto-allo-SCT.
We identified donor's age as a significant factor for survival after tandem. When donor's age was ≤50 years, OS was 54% (95% CI 41-67) versus 41% (95% CI 29-55), with p=0.02. In multivariable analysis, donor's age >50 years was an independent factor of worse OS with HR=1.99 (95% CI 1.22-3.25), p=0.006. When donor's age was >50 years, one year TRM was 24% (95% CI 15-36) versus 8% (95% CI 3-16), with p=0.006. No correlation was found between donor's age and allogeneic conditioning regimen (myeloablative or not), donor's type (sibling or unrelated) and HLA mismatches (data not shown). In our cohort, older donor's age failed to be associated to an increased incidence of GVHD and to a decreased cellularity of CD34+ allogeneic stem cell source (data not shown). Donor's age has been previously studied both in myeloablative and nonmyeloablative allogeneic conditioning settings (29) (30). It has been hypothesized that when donor's age is increasing, functional abilities of donor stem cells both in repopulation and homing are impaired (31) (32). Donor's T lymphocytes are also affected with telomere shortening and decreased effector activity (33). Altogether, immune reconstitution in recipients of allogeneic transplants from younger donors is better. The reasons for improved survival with a younger donor and potential link with GVM could not be further clarified in our study. Our results emphasize that donor's age should be a key criteria in the selection of MM patients for tandem auto-allo-SCT.
We report the French experience on the largest series published on tandem auto-allo-SCT in MM. In multivariable analysis, upfront tandem and donor's age ≤50 years were identified as two independent prognostic factors for improved survival. With the limits of a retrospective study, we underline that both patient pre-transplant characteristics (tandem as an upfront procedure) and intrinsic properties of stem cell source (donor's age) are important for tandem transplantation's outcome. Finally, our study was initiated before the introduction of novel agents-based induction and maintenance regimen. Therefore, the prognostic impact of these factors has to be further confirmed in prospective studies including new MM agents-based induction treatments (34) and post-transplant strategies of maintenance (35). 
